BLADE THERAPEUTICS
Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired diseases of fibrosis. Their leadership team has extensive experience at developing drugs that treat fibrotic disorders. They are also partnering with international experts in order to identify and in-license cutting-edge technologies to build a robust pipeline of antifibrotic compounds.
BLADE THERAPEUTICS
Industry:
Biopharma Health Care Pharmaceutical Therapeutics
Founded:
2013-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.blademed.com
Total Employee:
11+
Status:
Active
Contact:
+1 650 278 4291
Total Funding:
51.5 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Universal Analytics Apache Microsoft Exchange Online Office 365 Mail
Similar Organizations
1E Therapeutics
1E Therapeutics is a breakthrough, drug development company.
4E Therapeutics
4E Therapeutics is dedicated to developing treatments for neuropathic pain.
Ability Pharmaceuticals
Ability Pharmaceuticals is a drug discovery and development company.
Arkuda Therapeutics
Arkuda Therapeutics is a pharmaceutical company.
Click Therapeutics
Click Therapeutics delivers safe and effective digital treatments to patients in need.
Conler Pharm
Conler Pharm is the producer of API and finished drug development services.
Crystal Pharmatech
Crystal Pharmatech is a solid-state drug development firm.
JINRUI FOUNDATION
JINRUI FOUNDATION is a drug research and development company.
Sermonix Pharmaceuticals
Sermonix Pharmaceuticals is an Ohio LLC specialty pharmaceutical.
Astrotech
Astrotech operates as a science and technology development and commercialization company.
Topmunnity Therapeutics
Topmunnity Therapeutics is an oncology focused drug development company.
X-37
X-37 is a pharmaceutical discovery and development company
Current Advisors List
Board_member
2020-08-01
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Board_member
Current Employees Featured
Ravi Rajagopalan Executive Director, Drug Discovery Biology @ Blade Therapeutics
Executive Director, Drug Discovery Biology
2015-01-01
Felix Karim EVP, Business Development @ Blade Therapeutics
EVP, Business Development
2016-10-01
Shirley Chiang VP, Finance @ Blade Therapeutics
VP, Finance
2019-03-01
Wendye Robbins President & CEO @ Blade Therapeutics
President & CEO
Gary Patou Chief Medical Officer @ Blade Therapeutics
Chief Medical Officer
2018-10-01
Daven Mody VP, Regulatory Affairs & Quality @ Blade Therapeutics
VP, Regulatory Affairs & Quality
2019-04-01
Bassem Elmankabadi Senior Vice President of Clinical Development @ Blade Therapeutics
Senior Vice President of Clinical Development
2021-11-01
Prabha N Ibrahim Chief Technology Officer @ Blade Therapeutics
Chief Technology Officer
2017-04-01
Founder
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2019-09-25 | ATXCo | ATXCo acquired by Blade Therapeutics | N/A |
Investors List
OneVentures
OneVentures investment in Venture Round - Blade Therapeutics
Deerfield
Deerfield investment in Series B - Blade Therapeutics
Bristol Myers Squibb
Bristol Myers Squibb investment in Series B - Blade Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series B - Blade Therapeutics
Novartis Institutes
Novartis Institutes investment in Series B - Blade Therapeutics
Pfizer Venture Investments
Pfizer Venture Investments investment in Series B - Blade Therapeutics
MPM Capital
MPM Capital investment in Series B - Blade Therapeutics
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Series A - Blade Therapeutics
MPM Capital
MPM Capital investment in Series A - Blade Therapeutics
MPM Capital
MPM Capital investment in Seed Round - Blade Therapeutics
Key Employee Changes
| Date | New article |
|---|---|
| 2021-11-18 | Blade Therapeutics Appoints Bassem Elmankabadi, M.D., as Senior Vice President of Clinical Development |
Official Site Inspections
http://www.blademed.com
- Host name: ewhserver1302.edgewebhosting.net
- IP address: 69.63.140.80
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Blade Therapeutics"
Biotech Acquisition Company and Blade Therapeutics Announce …
Nov 8, 2021 Visit www.blademed.com for more information and follow Blade on LinkedIn. Important Information and Where to Find It This press release relates to a proposed merger …See details»
Blade Therapeutics - Crunchbase Company Profile & Funding
Blade Therapeutics is a discovery stage drug development company. Their mission is to create antifibrotic treatment strategies that address a wide variety of congenital and acquired …See details»
Blade Therapeutics Website Privacy Statement - blademed.com
May 10, 2021 An IP address is a number that is automatically assigned to your computer when you log on to your internet service provider or through your organization’s local area network …See details»
Blade Therapeutics - PitchBook
Blade Therapeutics General Information Description. Developer of novel anti-fibrotic therapies intended to revolutionize the treatment of fibrotic disease. The company's therapies address …See details»
Blade Therapeutics Announces FDA Orphan Drug ... - Business Wire
Oct 14, 2021 Media Relations – Michael Blash mblash@blademed.com +1-650-453-0632 Investor Relations – Krishna Gorti, M.D. kgorti@blademed.com +1-973-570-9438 Site NavigationSee details»
Blade Therapeutics Appoints Accomplished ... - Business Wire
Aug 5, 2020 Blade Therapeutics Wendye Robbins, M.D., President and CEO wrobbins@blademed.com Burns McClellan Cameron Radinovic Blade@burnsmc.com …See details»
Blade Therapeutics Appoints Accomplished ... - OneVentures
Aug 10, 2020 The Company has assembled critical leadership expertise supplemented by a world-class network of scientific, pharmaceutical and clinical advisors to enable efficient and …See details»
Blade Therapeutics Announces Successful Completion of Phase 1 …
Jan 12, 2022 Investors – Krishna Gorti, M.D. kgorti@blademed.com | +1-973-570-9438 Release Summary Blade Therapeutics, Inc. today announced the successful completion of a phase 1 …See details»
Blade Therapeutics to Participate in “Drug Development in
Aug 1, 2022 SAN FRANCISCO--(BUSINESS WIRE)-- Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and …See details»
Blade Therapeutics Announces Successful Completion of Phase
Jan 12, 2022 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Blade Therapeutics Inc. (“Blade”), a biopharmaceutical company focused on developing cutting-edge treatments for …See details»
Blade Therapeutics to Present at the Canaccord Genuity 39th …
Aug 1, 2019 South San Francisco, CA – August 1, 2019 – Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced that …See details»
Blade runs toward Nasdaq in $353M SPAC deal for 2 2022 trials, …
Nov 8, 2021 Blade Therapeutics will join the Nasdaq wave next quarter via a blank-check deal that will give the biotech about $255 million to bankroll trials in fibrosis and neurodegenerative …See details»
Blade Therapeutics Initiates Additional Phase 1 Clinical Study of ...
Oct 18, 2021 Visit www.blademed.com for more information and follow Blade on LinkedIn. Contacts Media Relations – Michael Blash mblash@blademed.com +1-650-453-0632 Investor …See details»
Blade Therapeutics Announces Positive Topline Data from Phase 1 ...
Nov 30, 2021 Visit www.blademed.com for more information and follow Blade on LinkedIn. On November 8, 2021, Biotech Acquisition Company (NASDAQ: BIOT), a special purpose …See details»
Blade Therapeutics to Present at the Stifel 2020 Virtual Healthcare ...
Nov 9, 2020 SOUTH SAN FRANCISCO, Calif., November 9, 2020 – Blade Therapeutics today announced that Wendye Robbins, M.D., President and Chief Executive Officer, will present at …See details»
Blade Therapeutics Mourns the Passing of General ... - Business Wire
Oct 11, 2021 Media Relations – Michael Blash mblash@blademed.com +1-650-453-0632 Investor Relations – Krishna Gorti, M.D. kgorti@blademed.com +1-650-797-0314 Release …See details»
Blade Therapeutics Expands Anti-Fibrotic Pipeline With ... - BioSpace
Sep 25, 2019 Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, …See details»
Blade Therapeutics, Inc. (Blade Therapeutics, Inc.) - 药物管线_专利_ …
了解Blade Therapeutics, Inc. (Blade Therapeutics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的11项临床试验, 19篇新闻，疾病领域:神经系统疾病，技术平台:小分子化药，化学 …See details»
Blade Therapeutics Reaches Enrollment Goal for Phase 2 Study of …
Sep 14, 2020 Visit www.blademed.com for more information. COVID-19 COVID-19 disease has quickly become a global pandemic with more than 27 million confirmed cases, nearly 900,000 …See details»
Blade Therapeutics Announces Positive Topline Data from Phase 1 ...
Nov 30, 2021 Investors – Krishna Gorti, M.D. kgorti@blademed.com | +1-973-570-9438 Release Summary Blade announces positive topline data from a phase 1 drug-drug interaction clinical …See details»